|1.||Matsuura, Eiji: 23 articles (11/2010 - 01/2002)|
|2.||Shoenfeld, Y: 14 articles (01/2008 - 06/2000)|
|3.||Kobayashi, Kazuko: 13 articles (11/2009 - 01/2002)|
|4.||Lopez, Luis R: 12 articles (05/2010 - 06/2003)|
|5.||Matsuura, E: 12 articles (05/2010 - 10/2000)|
|6.||de Groot, Philip G: 9 articles (10/2012 - 11/2002)|
|7.||Koike, Takao: 9 articles (10/2008 - 01/2002)|
|8.||Shoenfeld, Yehuda: 8 articles (08/2007 - 01/2002)|
|9.||Meroni, P L: 7 articles (06/2012 - 01/2000)|
|10.||Derksen, Ronald H W M: 7 articles (08/2010 - 11/2002)|
|1.||Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome)
01/01/2009 - "Studies on experimental antiphospholipid syndrome (APS) models proved that molecular mimicry between plasma protein beta(2)-glycoprotein I (beta(2)GPI) and structure within micro-organisms or their products, might be a cause for experimental APS. "
06/01/2012 - "Revisiting beta 2 glycoprotein I, the major autoantigen in the antiphospholipid syndrome."
04/01/2012 - "Beta2-glycoprotein I gene polymorphisms Val247Leu and Trp316Ser in Spanish patients with primary antiphospholipid syndrome."
07/01/2011 - "Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I."
08/26/2010 - "Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome."
|2.||Paraneoplastic Syndromes (Paraneoplastic Syndrome)
|3.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
01/01/1997 - "The dependence of anticardiolipin (aCL) binding on the presence of beta 2-glycoprotein I (beta 2-GPI) as a binding cofactor was assessed in these same groups, and was compared with sera from systemic lupus erythematosus (SLE) patients (n = 11) with raised aCL antibody reactivity. "
06/01/1999 - "To determine the frequency of mutations in the phospholipid binding domain of beta2-glycoprotein I (beta2GPI) in patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS), and to analyze the clinical correlations of such mutations with thromboembolic complications. "
09/21/2002 - "[Anti-beta 2-glycoprotein I antibodies and systemic lupus erythematosus]."
03/01/2002 - "Antiphospholipid (APL) antibodies (both anticardiolipin [ACAs] and anti-beta2 glycoprotein I [abeta2GPIs]) were present in 11/34 (32%) of the BD patients and in 54/73 (74%) of Omani patients with systemic lupus erythematosus (SLE) (chi2 = 21.2, P<0.001). "
04/01/2000 - "To investigate T-cell responses to beta(2)GPI, we stimulated PBMC of 18 APS or systemic lupus erythematosus (SLE) patients carrying anti-beta(2)GPI and 10 healthy controls, using a peptide library covering the beta(2)GPI sequence. "
04/01/2010 - "The pathophysiologic role of beta(2)GPI has been reported in the fields of coagulation, fibrinolysis, angiogenesis, and atherosclerosis. "
10/01/2001 - "Beta2-glycoprotein I and atherosclerosis."
08/01/2001 - "It seems that humoral and cellular immune responses to beta 2-glycoprotein I can play an important role in mediating the increased propensity to atherosclerosis."
06/29/2001 - "Apolipoprotein H (apoH) has been implicated in the development of human atherosclerosis. "
02/01/2001 - "beta 2-glycoprotein I in human and murine atherosclerosis."
03/01/2007 - "In this study, we analyzed genetic polymorphisms of beta (2)GPI in unselected Chilean patients to determine the prevalence of beta (2)GPI polymorphisms in the phospholipid domain in patients with venous and arterial thrombosis and the clinical correlation with thromboembolic complications. "
10/22/2009 - "We have recently found that beta2-glycoprotein I is able to inhibit platelet binding to VWF, indicating a role in the pathophysiology of arterial thrombosis. "
10/01/2008 - "The pathogenesis of antiphospholipid/anti-beta(2)GPI-associated thrombosis has not been defined, and is likely multifactorial. "
04/01/2008 - "It is generally accepted that the major autoantigen for aPL Abs is beta (2) glycoprotein I, which mediates the binding of aPL Abs to target cells (i.e., endothelial cells, monocytes, platelets, trophoblasts, etc.) leading to thrombosis and fetal loss. "
03/01/2007 - "Val/Leu247 and Trp/Ser316 polymorphisms in beta 2 glycoprotein I and their association with thrombosis in unselected Chilean patients."
|4.||LDL Receptors (LDL Receptor)
|7.||beta 2-Glycoprotein I (Apolipoprotein H)
|8.||Lupus Coagulation Inhibitor (Lupus Anticoagulant)
|9.||Immunoglobulin G (IgG)
|10.||Prothrombin (Factor II)